---
title: "Serina names Srini Tenjarla CTO; raises CEO Steve Ledger's salary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283560686.md"
description: "Serina has appointed Srini Tenjarla as Chief Technology Officer of its Serina (AL) subsidiary, effective April 20, 2026. Additionally, CEO Steve Ledger's annual base salary has been increased to $500,000, effective March 15, 2026. Tenjarla was previously the Senior Vice President of CMC and Formulation at Serina (AL) since July 2024. The salary increase for Ledger is in accordance with his employment agreement, contingent upon meeting specific strategic goals."
datetime: "2026-04-21T21:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283560686.md)
  - [en](https://longbridge.com/en/news/283560686.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283560686.md)
---

# Serina names Srini Tenjarla CTO; raises CEO Steve Ledger's salary

**Serina named Srini Tenjarla as Chief Technology Officer at its Serina (AL) subsidiary and increased CEO Steve Ledger's annual base salary to $500,000.**

Individual

Srini Tenjarla, Ph.D.

Steve Ledger

Role

Chief Technology Officer (Serina (AL) subsidiary)

Chief Executive Officer

Type of Change

Appointed / Promoted

Compensation Increase

Effective Date

April 20, 2026 (salary increase effective March 15, 2026)

April 15, 2026 (salary increase effective September 9, 2024)

Reason

Promotion from Senior Vice President of CMC and Formulation

Increase pursuant to employment agreement upon satisfaction of certain strategic goals

Replacement Info

Not disclosed

Not disclosed

Background Details

Previously Senior Vice President of CMC and Formulation at Serina (AL) since July 2024

Increase followed terms of employment agreement; retroactive portion paid in lump sum April 2026

Board/Committee Role Changes

Not disclosed

Not disclosed

Original SEC Filing: Serina Therapeutics, Inc. \[ SER \] - 8-K - Apr. 21, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SER.US](https://longbridge.com/en/quote/SER.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Insider-Backed PIPE Deal May Dilute Serina Therapeutics Shareholders and Heighten Governance Risks](https://longbridge.com/en/news/286635474.md)
- [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Black Diamond reports Phase 2 silevertinib mPFS 15.2 months in frontline EGFR-mutant NSCLC](https://longbridge.com/en/news/287274011.md)
- [Cardiff Oncology updates Phase 2 onvansertib data in first-line RAS-mutated mCRC trial](https://longbridge.com/en/news/287272648.md)